Elicio Therapeutics, Inc ( (ELTX) ) has released its Q4 earnings. Here is a breakdown of the information Elicio Therapeutics, Inc presented to its investors.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for treating high-prevalence cancers, particularly those driven by KRAS mutations. The company’s unique Amphiphile (AMP) technology aims to enhance cancer-specific T cell responses, offering potential advancements in cancer immunotherapy.
In its latest financial report, Elicio Therapeutics highlighted significant progress in its cancer immunotherapy pipeline throughout 2024. Key achievements include the completion of enrollment for the Phase 2 AMPLIFY-7P trial and alignment with the FDA on the design of the upcoming Phase 3 study for ELI-002. The company also strengthened its financial position with a $10 million stock offering to support ongoing operations.
Elicio reported a rise in research and development expenses to $33.7 million in 2024, reflecting increased clinical trial activities. Despite a net loss of $51.9 million for the year, the company improved its cash position to $17.6 million by the end of 2024. The Phase 2 AMPLIFY-7P trial, which completed enrollment of 144 patients, is set for an interim analysis in Q3 2025, with promising early data suggesting potential benefits in disease-free survival.
Looking ahead, Elicio Therapeutics is poised to advance its ELI-002 program into a pivotal Phase 3 trial in the second half of 2025, targeting KRAS-mutant pancreatic ductal adenocarcinoma. The company remains committed to leveraging its AMP platform to develop effective cancer vaccines and anticipates continued progress in its clinical programs.